NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: Correlation with biological parameters and response to treatment

Leukemia and Lymphoma

Volumn 55, Issue 12, 2014, Pages 2785-2792

  Chiaretti, Sabina ^a   Marinelli, Marilisa ^a   Del Giudice, Ilaria ^a   Bonina, Silvia ^a   Piciocchi, Alfonso ^b   Messina, Monica ^a   Vignetti, Marco ^a,b   Rossi, Davide ^c   Di Maio, Valeria ^a   Mauro, Francesca Romana ^a   Guarini, Anna ^a   Gaidano, Gianluca ^c   Foà, Robin ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b GIMEMA Foundation   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Chronic lymphocytic leukemia; First line treatment; Novel gene mutations

Indexed keywords

ALEMTUZUMAB; BIRC3 PROTEIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; NOTCH1 RECEPTOR; PROTEIN; PROTEIN KINASE ZAP 70; PROTEIN P53; RITUXIMAB; SF3B1 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIRC3 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; PHOSPHOPROTEIN; SF3B1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN; UBIQUITIN PROTEIN LIGASE;

ADULT; ARTICLE; CANCER SURVIVAL; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; GENE DISRUPTION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRISOMY 12; AGED; CLINICAL TRIAL (TOPIC); GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MORTALITY; MUTATION; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; PHOSPHOPROTEINS; PROGNOSIS; RECEPTOR, NOTCH1; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 84919452026     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.898760     Document Type: Article

References (37)

1. Zenz T, Mertens D, Küppers R, et al. From pathogenesistotreatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37-50.
2. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854.
3. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847.
4. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:1023-1029.
5. Gentile M, Mauro FR, Calabrese E, et al. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol 2005;130:549-557.
6. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775.
7. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901.
8. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
9. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
10. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia:clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994-4001.
11. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101-105.
12. Sportoletti P, Baldoni S, Cavalli L, et al. NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. Br J Haematol 2010;151:404-406.
13. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome:role of NOTCH1 mutational activation. J Exp Med 2011;208:1389-1401.
14. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012;119:521-529.
15. Balatti V, Bottoni A, Palamarchuk A, et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012;119:329-531.
16. Del Giudice I, Rossi D, Chiaretti S, et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional Profiling and ref ne the intermediate prognosis of + 12 CLL. Haematologica 2012;97:437-441.
17. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia:Association with progression and fludarabine-refractoriness. Blood 2012; 118: 6904-6908.
18. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365:2497-506.
19. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2011; 44: 47-52.
20. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012; 119: 2854-2862.
21. Foà R, Del Giudice I, Guarini A, et al. Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica 2013; 98: 675-685.
22. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013; 121: 1403-1412.
23. Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013;121:468-475.
24. Schnaiter A, Paschka P, Rossi M, et al. NOTCH1, SF3B1 and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood 2013;122:1266-70.
25. Mauro FR, Molica S, Laurenti L, et al. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profle. Leuk Res 2013 Nov 19. [Epub ahead of print]
26. Foà R, Del Giudice I, Cuneo A, et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol 2014 Jan 11. [Epub ahead of print]
27. Del Giudice I, Mauro FR, De Propris MS, et al. White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia. Haematologica 2011;96:626-630.
28. Ghia P, Stamatopoulos K, Belessi C, et al.; European Research Initiative on CLL. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia 2007; 21: 1-3.
29. Pospisilova S, Gonzalez D, Malcikova J, et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012; 26: 1458-1461.
30. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997.
31. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
32. Gonzalez D, Martinez P, Wade R, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011;29:2223-2229.
33. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473-4479.
34. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15:995-1004.
35. Stilgenbauer S, Busch R, Schnaiter A, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2012;120(Suppl. 1): Abstract 433.
36. Guarini A, Marinelli M, Tavolaro S, et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica 2012;97:47-55.
37. Dreger P, Schnaiter A, Zenz T, et al. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood 2013;121:3284-3288.